South Africa is one of five countries to participate in Sinovac’s CoronaVac trial. The global trial will enrol 14 000 children, aged between 6 months and 17 years. The COO of Numolux, acting on behalf of Sinovac, Anton Arendse, says the CoronaVac vaccine is safe and has been approved for use by SAHPRA. Phase 1 and 2 trials in China have shown CoronaVac is well-tolerated in children and adolescents aged 3-17 years and induces a strong immune response. SAHPRA and the World Health Organisation have approved the global trial.